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The present review is a thematic summary of the
research evidence base for the effectiveness and main
influential factors of contemporary drug abuse treat-
ment. The review is designed to be a companion
resource to the section on effective treatment and reha-
bilitation services in the publication "Drug abuse treat-
ment and rehabilitation: a practical planning and imple-
mentation guide" and to the document entitled
"Investing in drug abuse treatment: a discussion paper
for policy makers".
Most of the evidence for the impact of treatment comes
from randomized controlled trials and uncontrolled
observational evaluations of treatments and treatment
systems. Both types of study assess the severity of prob-
lems for a sample of patients at intake to a treatment
programme and then measure changes in those prob-
lems at one or more points during and after treatment.
Experimental studies involve random assignment of
groups of patients to specific interventions and compar-
ison conditions. Where they are feasible, experimental
designs offer the most convincing evidence on treat-
ment efficacy. Observational evaluations are often large-
scale activities that examine how effectively one or more
types of treatment programme are delivered and how
patients are assigned to them, but they include no
manipulation of treatment conditions. Such studies are
useful when there are general questions about the effec-
tiveness of a treatment system; they can indicate if out-
come expectations are achieved and how benefits of
treatment vary across programmes and with the amount
or type of treatment that patients receive. 
A comprehensive survey of the relevant literature is
beyond the remit of the present concise review and the
cited studies are representative of a well-studied area or
are notable for investigating a specific issue. The scope of
the review is international. Most of the evidence for the
effectiveness of treatment has been published by research
groups working in the United States of America, in
Europe and in several countries in the region of Asia and
the Pacific, notably Australia. The summarized evidence
presented here reflects that geographical reality, but can-
not be said to be a comprehensive summary of the evi-
dence from across the globe. Moreover, the reader will
need to judge the extent to which the summarized find-
ings can be applied to his or her own specific culture and
treatment service-delivery context. No attempt is made
to contrast directly the results of studies conducted on
specific treatment modalities across different nations.
There are often substantial differences in the nature of
patients treated and the structure and operation of the
treatment systems that make such comparisons uninfor-
mative. It is, however, worth noting that the findings for
the impact of the main forms of structured treatment are
remarkably similar across national and cultural divides.
The review has been limited to work published in peer-
reviewed, scientific journals in English. All of the research
cited has used methodologically sound observational,
naturalistic or controlled, experimental designs. A litera-
ture search was performed using Embase, Pubmed,
Medline, PsychInfo and Cochrane databases from 1980
to May 2002.
Structure of the review
The review consists of three sections. Parts 1 and 2 pres-
ent research evidence for the effectiveness of the detoxi-
fication-stabilization phase and the rehabilitation-
relapse prevention phase, respectively. Those phases
contain treatments that have distinct goals, objectives
and methods and are delivered in residential and com-
munity settings. Part 3 presents a discussion on a set of
patient-related and treatment-related factors that are
linked to treatment outcome. Patient-related factors
include the severity of substance abuse, psychiatric
symptoms, treatment readiness and motivation,
employment and family and social support. Treatment-
related factors include the setting of treatment, treat-
ment completion and retention, pharmacotherapies,
counselling, counsellor and therapist effects, participa-
tion in self-help groups and issues concerning matching
patients to treatment.
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Introduction
Patients and treatment methods
The detoxification and stabilization phase of treatment is
designed for people who experience withdrawal symp-
toms following prolonged abuse of drugs. Detoxification
may be defined as a process of medical care and pharma-
cotherapy that seeks to help the patient achieve absti-
nence and physiologically normal levels of functioning
with the minimum of physical and emotional discomfort
[1].  Pharmacotherapy involves the administration of a
suitable agonist medication, in progressively diminishing
amounts, to minimize withdrawal discomfort from opi-
oid, barbiturate and benzodiazepine dependence, where a
characteristic rebound physiological and emotional with-
drawal syndrome is experienced usually around 8-12
hours following the last dose of the drug. Users of
amphetamine and cocaine may also experience substan-
tial emotional and physiological symptoms and will
require a period of stabilizing treatment. 
Indicators of effectiveness
The main goals of this phase include the safe manage-
ment of medical complications, the attainment of absti-
nence and the motivation of a patient's cognitive and
behavioural change strategies that are to be the focus of
further rehabilitation efforts. On its own, detoxification
is unlikely to be effective in helping patients achieve
lasting recovery; this phase is better seen as a preparation
for continued treatment aimed at maintaining absti-
nence and promoting rehabilitation [2, 3].
Pharmacotherapies
The evidence suggests that detoxification from illicit
heroin and other opioids can be facilitated using dose-
tapered opioid agonists (mainly methadone), the partial
antagonist buprenorphine and two non-opioid drugs,
clonidine and lofexidine (both 2-adrenergic agonists).
However, evaluating the relative merits of those medica-
tions is hampered by differences in the operation of treat-
ment programmes and various measurement issues to do
with clinical assessments of withdrawal symptom seve-
rity. Allowing for this caveat, Gowing and colleagues con-
ducted a Cochrane review of 218 international detoxifi-
cation studies and calculated mean completion rates for
inpatients and outpatients setting opioid detoxification
of 75 per cent and 35 per cent, respectively, when using
methadone and 72 per cent and 53 per cent, respective-
ly, when using an 2-adrenergic agonist [4]. Several ran-
domized controlled trials have contrasted between
buprenorphine and clonidine. Results suggest that
buprenorphine is better at reducing the severity of with-
drawal symptoms and leads to fewer adverse effects [5].
Procedures for accelerating the time required for opioid
detoxification using opioid antagonists have been avail-
able for several decades [6]. The rapid opioid detoxifica-
tion (RD) precipitates withdrawal with naloxone or nal-
trexone, while ultrarapid opioid detoxification (URD)
administers naloxone or naltrexone under anaesthesia or
deep sedation. Both techniques induce a severe but short
withdrawal syndrome and have been developed and stud-
ied in several countries [7-10]. In a comprehensive review
of 12 RD and 9 URD studies, O'Connor and Kosten
note that substantial methodological variation hampers
interpretation of the literature, which is also character-
ized by small sample sizes and generally short follow-up
periods [11]. The general conclusion from these studies is
that while URD has some medical risks, those techniques
do not confer substantial advantage over existing detoxi-
fication methods, nor are they more successful in induct-
ing and retaining abstinent patients in relapse prevention
pharmacotherapy using naltrexone. 
Length of stay
Stabilization of acute withdrawal problems is typically
completed within 3-5 days, but this may need to be
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phase of treatment
extended for patients with conjoint medical or psychi-
atric problems or physiological dependence upon ben-
zodiazepines and other sedatives [12, 13]. For
methadone, the Gowing group's review suggests that,
when detoxification extends for more than 21 days, the
mean rate of treatment completion is 31 per cent. This
compares with 58 per cent for treatment completed in
21 days or less. The authors note that this may reflect
treatment-setting effects to some extent, as 89 per cent
of the studies that have a longer duration of detoxifica-
tion were conducted in a community setting. 
Treatment setting
There has been much debate and study of the relative
effectiveness of detoxification treatment in hospital
inpatient or other residential settings or in outpatient or
community-based settings [14, 15]. Residential settings
are generally associated with better completion rates,
but in most countries the prevailing practice is to stabi-
lize all but the most severely affected patients in outpa-
tient settings. For example, for patients with cocaine
dependence, the literature is replete with accounts of
early dropouts during the first 14-21 days of outpatient
treatment, with attrition rates ranging from 27 per cent
to 47 per cent in the first few weeks of care [16-18].
Detoxification is generally viewed as particularly appro-
priate for patients who present with acute medical and
psychiatric problems (in particular those with a history
of seizure and depression) and also those who have con-
current acute alcohol dependence. Studies of shorter-
term outpatient reduction programmes have generally
reported poor outcomes with high patient dropout and
few achieving abstinence [19]. However, those patients
who have less acute problems and medical complica-
tions and have a stable, supportive home situation may
well be able to complete detoxification in the commu-
nity [20]. Few studies have examined the appropriate
setting for the stabilization of physiological and 
psychiatric signs and symptoms associated with psycho-
stimulant use; however, a residential medical setting is
generally required if the patient has acute psychiatric
symptoms and emotional distress. 
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Patients and treatment methods
Rehabilitation is appropriate for patients who are no
longer suffering from the acute physiological or emo-
tional effects of recent substance abuse. Goals of this
phase of treatment are to prevent a return to active sub-
stance abuse, to assist the patient in developing control
over urges to abuse drugs and to assist the patient in
regaining or attaining improved personal health and
social functioning.
Treatment elements and methods
Professional opinions vary widely regarding the under-
lying reasons for the loss of control over alcohol and/or
drug use typically seen in treated patients. A number of
explanatory mechanisms have been suggested, including
genetic predispositions, acquired metabolic abnormali-
ties, learned, negative behavioural patterns, deeply
ingrained feelings of low self-worth, self-medication of
underlying psychiatric or physical medical problems
and lack of family and community support for positive
function. There is an equally wide range of treatment
strategies and treatments that can be used to correct or
ameliorate those underlying problems and to provide
continuing support for the targeted patient changes.
Strategies have included such diverse elements as med-
ications for psychiatric disorders; medications to relieve
drug craving; substitution pharmacotherapies to attract
and rehabilitate patients; group and individual coun-
selling and therapy sessions to provide insight, guidance
and support for behavioural changes; and participation
in peer help groups (e.g. Narcotics Anonymous) to pro-
vide continued support for abstinence. 
Duration
Short-term residential rehabilitation programmes are
typically delivered over 30-90 days; residential 
therapeutic community programmes usually range from
three months to one year; outpatient, abstinence-
oriented counselling programmes range from 30 to 120
days; and methadone maintenance programmes can
have an indefinite time period. Many of the more inten-
sive forms of outpatient treatment (e.g. intensive outpa-
tient and day hospital) begin with full- or half-day ses-
sions five or more times per week for approximately one
month. As the rehabilitation progresses, the intensity of
the treatment is reduced to shorter sessions of one to
two hours delivered twice a week and then tapering to
once a week. The final stage of outpatient treatment is
typically called “continuing care” or “aftercare”, with
biweekly to monthly group support meetings (in associ-
ation with parallel activities in self-help groups) contin-
uing for as long as two years.
Defining outcome domains
The effectiveness of this phase of treatment can be
judged against three outcome domains that are relevant
both to the rehabilitative goals of the patient and to the
public health and safety goals of society: (a) elimination
or reduction of alcohol and drug use; (b) improved
health and functioning; and (c) reduction in public
health and public safety threats. The threats to public
health and safety from substance abusing individuals
come from behaviours that spread infectious diseases
(including blood exchange arising from unprotected
penetrative sex and sharing needles and other injection-
related equipment) and engaging in crime to fund or
sustain drug abuse. Regardless of the specific setting,
modality, philosophy or methods of rehabilitation, all
forms of rehabilitation-oriented treatment for addiction
have the following four goals: (a) to maintain physio-
logical and emotional improvements initiated during
detoxification-stabilization; (b) to enhance and sustain
reductions in alcohol and drug use (most rehabilitation
programmes suggest a goal of complete abstinence); 
(c) to teach, model and support behaviours that lead to
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6improved personal health, improved social function and
reduced threats to public health and public safety; and
(d) to teach and motivate behavioural and lifestyle
changes that are incompatible with substance abuse. 
Main effects of residential treatment
There is a sizeable and long-standing body of interna-
tional research evidence for the positive impact of res-
idential programmes in the three outcome domains
[21-24]. By way of a typical example, results from 
the largest major evaluation of residential rehabili-
tation programmes in the United States showed the
following reductions in the proportion of patients
using illicit substances at least once a week during the
year prior to admission and during the year following
departure from treatment: the proportion of patients
using cocaine decreased from 66 to 22 per cent; the
proportion using cannabis, from 28 to 13 per cent;
and the proportion using heroin, from 17 to 6 per
cent [25]. Clients who complete treatment also
achieve better employment and are substantially less
likely to be involved in crime [26]. However, dropout
from residential rehabilitation does seem to be a com-
mon problem, and studies typically report attrition
levels of 25 per cent of patients within two weeks and
40 per cent by three months [27].
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Severity of substance use
A variety of studies of treatments in different national
contexts have shown that the chronicity and severity of
patients' substance use patterns have been reliably associ-
ated with poorer retention in treatment and more rapid
relapse to substance use following treatment [28-30].
Severity of psychiatric problems
International epidemiological population surveys and
clinical studies have shown that people with substance
abuse and dependence disorders are prone to have anxi-
ety, affective and anti-social and other personality disor-
ders [31-34]. Outcome studies of dependent opioid-
and cocaine-abusing patients suggest that, for most
patients, psychiatric symptoms improve early on in
treatment and that, on average, there are sustained
reductions in symptom levels over medium- and long-
term follow-up [35]. However, a consistent finding
across many studies and contexts is that severe psychi-
atric symptoms and disorders at intake to treatment are
a reliable predictor of dropout and poorer follow-up
outcomes [36-41]. 
Treatment readiness and motivation
Patients who report being ready and motivated to
receive treatment tend to engage more successfully with
the therapeutic programme and stay in treatment for
longer periods of time [42]. Interestingly, patients who
have been mandated to enter substance abuse treatment
have shown outcomes that are quite similar to those
who are self-referred and supposedly more “internally
motivated” [43, 44].
Employment
Many people with drug abuse problems have enduring
difficulties with obtaining and retaining paid employ-
ment. Unemployed patients are more likely to drop out
of treatment prematurely and to relapse to substance
abuse [45-47]. Although the ability of a treatment pro-
gramme to secure a job for a client may be limited, com-
munity services will usually seek to help a client to
improve employment opportunities and securing or
maintaining a job is recognized as an important goal
[48]. Employment has been found to predict retention
in treatment and good outcome [49]. For example, in a
sample of primarily employed, multiple substance
abusers entering private inpatient or outpatient pro-
grammes, McLellan and colleagues showed that
employment problems were one of the most significant
predictors of post-treatment substance abuse and other
aspects of poor health and social functioning [50].
Family and social supports
Social supports have been widely studied in the drug
abuse and dependence field. Social support has been
conceptualized variously as the availability of rela-
tionships that are not conflict-producing and supportive
of abstinence; and the active participation in peer-
supported treatments such as Narcotics Anonymous
[51, 52]. Stressful life events (such as the loss of a job,
bereavement or the ending of a personal relationship)
may exert a more powerful effect in determining indi-
vidual outcomes than treatment itself [53]. It follows that
treatment goals may not be reached at all or may attenu-
ate rapidly following treatment if the patient's environ-
mental resources are limited. Effective treatments for sub-
stance abuse look beyond the programme to assist the
patient in becoming included in society and improving
family relationships and personal resources [54].
3. Effective components in the 
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Setting of treatment
Many studies have investigated differences in effective-
ness between various forms of hospital inpatient and
outpatient/day rehabilitation treatments. Much of the
literature concerns alcohol dependence and has repor-
ted positive main effects for treatment and generally few
interactions with setting [55]. Experimental studies of
inpatient or outpatient treatment for cocaine depend-
ence have resulted in the same conclusion [17, 41]. For
example, Alterman and colleagues [41] compared the
effectiveness of four weeks of intensive, highly struc-
tured day hospital treatment (27 hours weekly) with
inpatient treatment (48 hours weekly) for cocaine
dependence. The subjects were primarily inner city,
male African Americans treated at a United States
Veterans Administration Medical Center. The inpatient-
treatment completion rate of 89 per cent was signifi-
cantly higher than the day-hospital completion rate of
54 per cent. However, at seven months after treatment,
self-reported outcomes indicated considerable improve-
ments for both groups in drug and alcohol use, family/
social, legal, employment and psychiatric problems. The
comparability of the two treatment settings was also evi-
dent in 12-month outcomes [54]. The general conclu-
sions from this work are that, for most treatment 
systems, it is likely that patients who have sufficient per-
sonal and social resources and who present with no seri-
ous medical complications should be assessed for out-
patient/day treatment. Given the typically high demand
for residential care, it seems logical to prioritize that set-
ting for those with acute and chronic problems who
have social stressors and/or environments that are likely
to interfere with treatment engagement and recovery.
Treatment completion and retention
There is a substantial amount of literature to support
the assumption that patients who complete treatment
will have better outcomes than those who leave prema-
turely. Generally, longer stays in outpatient mainte-
nance and residential rehabilitation programmes are
related to better follow-up outcomes [46, 56]. Benefits
increase with time in the programme and retention is a
fairly reliable proxy measure of success for most types
of treatment. Given that most people who are studied
in drug abuse treatment programmes have chronic and
diverse problems, it is to be expected that the longer
they remain in treatment, the greater the likelihood
that significant lifestyle improvements will be achieved
and consolidated. A consistent finding from the
United States' national outcome studies is that patients
who stay for at least three months in residential pro-
grammes have superior post-departure outcomes than
patients with shorter stays [57]. In a landmark study,
aggregate data from a sample of patients entering thera-
peutic community programmes showed that remaining
in treatment for one year or more is significantly relat-
ed to improvements at 12-month post-discharge fol-
low-up [46]. This finding has been replicated in the
United Kingdom of Great Britain and Northern
Ireland, where the greatest levels of abstinence for opi-
oid abuse at one-year follow-up were associated with
28 days of inpatient and shorter-stay residential partic-
ipation (effectively a measure of programme comple-
tion) and 90 days in the longer-term residential pro-
grammes [58]. Also, patients who stay for at least one
year in outpatient methadone treatment have substan-
tially better outcomes than those who leave before that
point [29, 42]. There is less clear-cut evidence for the
retention and duration effects of community absti-
nence-oriented counselling services. To date, no link
has been found between treatment duration and out-
come for such services [42]. This may be due to diver-
sity in organizational practices and patient differences.
The time spent in treatment does not directly mediate
good outcome. Staying in treatment enables the patient
to acquire new skills and to make progress in the pro-
gramme. For example, Toumbourou and colleagues
reported outcomes for a sample of Australian patients
who had been treated in a therapeutic community [59].
The time spent in treatment was related positively to
improved outcomes, but the extent or level of therapeu-
tic progress attained emerged as a stronger predictor of
outcome than simply the time spent in treatment.
Overall, the issue of how long patients are able to spend
in treatment is a key fiscal issue for most treatment sys-
tems. The implications of this work are that treatment
service personnel and the wider care coordination infra-
structure should ensure that patients are retained in
treatment for at least the minimum threshold for suc-
cess, and where possible, treatment duration should be
determined by patient need. There are also important
implications for targeting people who leave treatment at
an earlier point, since those individuals are characterized
by substantially poorer outcomes.
Pharmacotherapies
Several main forms of pharmacotherapy for opioid
dependence have been developed and widely evaluated
for their role in the rehabilitation-relapse prevention
phase [60]. 
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Agonist medications
Methadone
Originally developed in the mid-1960s in New York, daily
dosing with methadone prevents withdrawal symptoms
for approximately 24 hours. After initial trials, the treat-
ment was extended to other localities across the United
States and has been evaluated in considerable depth by
American research groups in single- and multi-site evalu-
ations across three decades and more recently by evalua-
tors in many other countries. Those efforts have estab-
lished a considerable international treatment base for oral
methadone maintenance treatment and an impressive
research evidence base for its effectiveness [56, 61]. For
example, a recent national cohort study in the United
Kingdom has reported sustained reductions in heroin
abuse among patients who entered methadone mainte-
nance treatment after six months and one- and two-year
follow-ups [24, 38, 62]. A robust finding is that the dose
of methadone has a positive linear relationship with reten-
tion in treatment and a negative linear relationship with
heroin abuse. For example, Ling and his colleagues
showed that 100 milligram (mg)/day was superior to 
50 mg as indicated by staff ratings of global improvement
and by a drug use improvement index based on urine 
testing [63]. In a study of moderate (40-50 mg) and high
(80-100 mg) dose methadone, Strain and his colleagues
found a significantly lower rate of opiate positive urine
specimens among patients receiving the high dose of
methadone (53 per cent versus 62 per cent) [64]. Several
studies have shown that people on higher doses (around
50 mg/day and above) are more likely to be retained in
treatment and less likely to continue to abuse heroin [56,
65]. For example, one study that assigned patients ran-
domly to higher or lower dose methadone maintenance
found that the proportion of toxicology tests that were
positive for opioids was 45 per cent for the higher-dose
group compared with 72 per cent for the lower-dose
group [66]. In a similar study Strain's group found a high-
dose regimen to be associated with significantly lower
rates of opioid-positive urine samples, although there was
no significant difference in rates of retention [67].
As an overall summary of the impact of methadone treat-
ment, Marsch conducted a statistical meta-analysis of 11
studies that reported illicit opioid use, 8 studies that
reported on human immunodeficiency virus (HIV) risk
behaviours and 24 studies reporting on changes in crim-
inal involvement [61]. Her review showed that there is a
consistent statistically significant relationship between
maintenance treatment and the reduction of illicit opioid
use, HIV risk behaviours and drug and property crimes.
Kreek has concluded that methadone maintenance with
adequate doses of medication and access to counselling
and medical and psychiatric care leads to voluntary one-
year retention of 60-80 per cent with reduction of daily
illicit opioid use from 100 per cent on entry to treatment
to less than 20 per cent within one year [68].
Levoalphacetylmethadol
Levoalphacetylmethadol (LAAM) is a longer acting
form of methadone. Dosing in the range of 70-100 mg
is capable of suppressing withdrawal symptoms for 48-
72 hours and permits administration three times a week
[69]. Rawson and his colleagues summarized findings
from 27 trials of oral LAAM involving more than 4,000
patients and concluded that LAAM achieved compara-
ble outcomes to methadone [70]. A meta-analysis of
randomized controlled trials concluded that, while
LAAM and methadone maintenance were of equivalent
effectiveness in terms of capacity to reduce illicit drug
use, there were small but statistically significant differ-
ences favouring methadone maintenance in treatment
retention rates and rates of discontinuation of treatment
because of side effects [71]. LAAM may, however, be
permanently withdrawn in Europe following 10 cases of
life-threatening cardiovascular complications. The
United States authorities have examined the issue but
have not taken the same action as the European author-
ities to date. Recently Clark and colleagues have repor-
ted the results of a Cochrane review of 15 randomized
controlled trials and 3 controlled prospective studies to
compare LAAM with methadone maintenance [72].
They concluded that LAAM appeared to be more effec-
tive at reducing heroin abuse than methadone.
However, there are insufficient data in the published
evidence to comment on uncommon adverse events. 
Buprenorphine
Buprenorphine is a synthetic opioid partial agonist with
mixed agonist and antagonist properties. It was originally
recognized in the 1970s as a potentially useful treatment
for opioid dependence [73]. Research has shown
buprenorphine to be an effective maintenance agent and
to have a better safety profile in overdose than methadone
and other agonists [74-76]. Buphrenorphine (Subutex®)
has been used for many years in France [77] for mainte-
nance treatment of dependent heroin users. There is now
a growing number of patients treated with buprenorphine
in several other European countries, including Austria
[78], Switzerland [79] and the United Kingdom. There is
also interest in this treatment agent in the region of Asia
and the Pacific and an ongoing research and development
programme in Australia [80].
The general view is that buprenorphine can be pre-
scribed in higher doses in maintenance treatment with-
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out undue sedation. Ling and his colleagues have report-
ed results from a multi-centre, double-blind trial of
treatment in 12 sites in the United States and Puerto
Rico  [81]. The team contrasted 1 mg/day and 8 mg/day
and found that the higher-dosing group achieved signif-
icantly better retention and drug use outcomes.
Buprenorphine is also effective for detoxification, pro-
ducing less severe and protracted withdrawal symptoms
than methadone [79, 82]. Another advantage of
buprenorphine is that it has a longer half-life than
methadone and is capable of less than daily dosing. The
research evidence suggests that a doubled dose every two
days or a tripled dose every three days are acceptable to
patients and do not induce untoward agonist or with-
drawal effects [83, 84].
Further research and development work is now required
to assess the patient groups and delivery arrangements
best suited to buprenorphine maintenance. At the time
of writing, buprenorphine has not yet been approved for
use in the United States.
Antagonist medications
Naltrexone
The opioid antagonist naltrexone may be used as part of
relapse prevention programmes. A single maintenance
dose of naltrexone binds to opioid receptor sites in the
brain and blocks the effects of any opioids taken for the
next 24 hours. It produces no euphoria, tolerance or
dependence. Patients generally require 10 days of absti-
nence before induction onto naltrexone (but see the
accelerated detoxification procedures above). The effec-
tiveness of naltrexone treatment clearly hinges on a
patient's compliance with treatment and the motivation
to take their medication each day. In the largest multi-site
study comparing naltrexone with placebo, compliance
was found to be the main weakness of this treatment
[85]. Patient attrition from the trial was substantial, with
543 of 735 people selected for inclusion failing to com-
mence treatment; of the 192 who did begin treatment
just 13 (7 of 60 in the naltrexone group and 6 of 64 in
the placebo group) completed their scheduled nine-
month programme. This has been a general problem
with naltrexone outcome studies. In their review of 11
evaluations, Tucker and Ritter note that, in 4 studies, of
those patients who were offered naltrexone, between 3
per cent and 49 per cent actually commenced treatment;
in a further 5 studies, between 23 per cent and 58 per
cent of participants left within the first week; and in
another 4 studies between 39 per cent and 74 per cent of
participants left treatment by the end of the second week
[86]. These reviewers also identified nine studies that
involved unselected participants (i.e. those not necessarily
demonstrating high motivation or with external rein-
forcers for abstinence). In these studies retention periods
varied between 43 days and eight months. Several inter-
esting outcome studies have compared naltrexone and
methadone maintenance treatment. In one, 60 consecu-
tive patient admissions were able to select which of the
treatments they wished to enter [87]. The patients in the
methadone group were retained in treatment significant-
ly longer than those in the naltrexone group; 8 of 30 nal-
trexone patients compared with 26 of 30 methadone
patients remained in treatment for the full 12 weeks of
treatment. However, there were no differences in illicit
heroin abuse during treatment or in the numbers attain-
ing complete abstinence. Finally, a large cohort study in
Italy reported one-year retention rates for 40 per cent of
patients in methadone maintenance and 18 per cent for
those in naltrexone treatment [88]. In contrast, for
highly motivated or compliant patients, the effectiveness
of naltrexone is generally good (at least for the duration
of treatment). For example, Brahen and colleagues
reported a retention rate of 75 per cent when naltrexone
treatment was used as part of a prisoner work-release pro-
gramme [89]. In another study 61 per cent of business
executives and 74 per cent of physicians remained in nal-
trexone treatment for six months with good outcomes
[90]. A Cochrane review of naltrexone concludes that the
available trials do not permit a firm assessment of the
worth of naltrexone maintenance, but the data do sup-
port this treatment approach for those who are highly
motivated and when used in conjunction with various
psychosocial therapies (see below) [91].
Cocaine antagonists, agonists and adjunctive pharma-
cotherapies
There have been many attempts to develop antagonists
for the treatment of cocaine dependence; while the
research is quite extensive, the results have been disap-
pointing [92, 93]. At the time of writing, there is no
convincing evidence that any of the various types of
cocaine blocking agent are truly effective for even a sig-
nificant minority of affected patients. Research contin-
ues in this important area and there have been indica-
tions of a potentially successful “vaccine” that may be
able to immediately metabolize and inactivate active
metabolites of cocaine [94]. This promising work is cur-
rently being tested in animal models, but there are no
treatment relevant medications available for cocaine
rehabilitation at the present time.
People who have acute cocaine dependence experience
depletion in levels of the neurotransmitter dopamine.
Dopamine agonists have been proposed as an effective
treatment for managing cocaine withdrawal, craving
and negative mood effects. Amantadine and bromocrip-
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tine have been the most widely studied [95]. A
Cochrane review by Soares and colleagues of 12 placebo-
controlled studies has concluded that there is no sig-
nificant effect of these medications [96]. Several types of
(mainly tricyclic) anti-depressant have also been evalu-
ated as pharmacotherapy for cocaine withdrawal symp-
toms and dysphoria. In two Cochrane reviews of 23
studies, Lima and colleagues concluded that the overall
evidence was not favourable, principally because of high
patient dropouts [97, 98].
Counselling
Access to regular substance abuse counselling can make
an important contribution to the engagement and par-
ticipation of the patient in a treatment programme and
to its outcome [99, 100]. For example, in an important
study, patients in methadone maintenance were ran-
domly assigned to receive counselling or no counselling
in addition to their methadone dose [101]. Results
showed that 68 per cent of patients assigned to the no-
counselling group failed to reduce drug abuse and that
one third of those patients required at least one episode
of emergency medical care. In contrast, 63 per cent of
the patient group assigned to receive counselling showed
sustained elimination of opiate use and 41 per cent
showed sustained elimination of cocaine use over the six
months of the trial. The positive impact of individual or
group counselling and attendance at 12-step meetings
has been observed in another study where greater fre-
quency of attendance at counselling and self-help
groups were associated with lower risk of relapse over
the subsequent six months [102]. Several types of coun-
selling and behavioural treatments have been studied, as
described below.
General outpatient drug-free counselling
General outpatient drug-free counselling provision in
the United States has been evaluated in a variety of stud-
ies and by national outcome investigations. Results sug-
gest that abstinence-oriented counselling is associated
with reductions in drug use and crime involvement
together with improvements in health and well-being
[103]. In one study, the proportion of patients using
cocaine weekly or more frequently dropped from 41 to
18 per cent at one-year follow-up, while weekly or more
frequent cannabis use was reduced from 25 to 9 per cent
and heroin from 6 to 3 per cent [25]. In a study of coun-
selling for cocaine dependence, Alterman's group con-
trasted a structured day programme delivering around
30 hours of counselling per week with an intensive four-
week inpatient programme [41]. Substantial improve-
ments were seen for patients in both treatment settings
at 7- and 12-month follow-up [54]. Another evaluation
demonstrated that increased frequency of attendance in
individual and group counselling in community coun-
selling treatment was related to a lower risk of relapse
over a six-month follow-up [102].
Specific cognitive psychotherapies
A group of studies has also examined the relative effec-
tiveness of general counselling or specific forms of psy-
chotherapy. In one study, patients were randomly
assigned to receive standard non-specific counselling or
counselling with the addition of either supportive-
expressive psychotherapy or cognitive-behavioural psy-
chotherapy over six months [104]. Results showed that
patients receiving psychotherapy showed greater
improvements in illicit drug use, health and crime
involvement than those receiving standard counselling.
In a contrasting study, Crits-Christoph and colleagues
randomly assigned patients with cocaine dependence
to six months of 12-step group counselling only or to
one of three forms of supplementary individual coun-
selling (12-step, cognitive psychotherapy or supportive
expressive psychotherapy) [105]. Results showed that
reductions in cocaine use were greater amongst those
patients receiving both group and individual 12-step
counselling. Patients receiving the supplementary cog-
nitive psychotherapies were found to have equivalent
outcomes to the patients receiving group counselling
only. 
William Miller and his colleagues have developed a style
of brief therapeutic intervention known as “motivational
interviewing” designed to facilitate a patient’s internally
motivated commitment to change [106]. This has been
applied in the context of treating heroin users. In
Australia, Saunders and colleagues reported the results
of using a one-hour motivational session using a con-
trolled trial design with patients receiving methadone
maintenance [107]. At six-month follow-up, patients
who received the motivational intervention reported less
illicit drug use, remained in treatment longer and
relapsed to heroin use less quickly as compared with
controls. Brief motivational counselling techniques have
also been adapted for the treatment of cannabis use dis-
orders and positive results have been reported in two
United States trials [108, 109] and also by a research
team working in Australia [110, 111].
Cognitive-behavioural approaches
Of all the psychosocial counselling approaches, relapse-
prevention-oriented cognitive-behavioural therapy has
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received the most frequent evaluation. Considerable
research efforts have gone into evaluating the effective-
ness of cognitive-behavioural therapy with patients with
alcohol dependence, focusing on social and communi-
cation skills training, stress and mood management and
assertion training [112-115]. A smaller set of studies has
addressed the impact of the treatment with other drug
abusers, with favourable results [116, 117]. In the
United States, several cognitive-behavioural therapy
protocols, notably contingency reinforcement therapy,
that incorporate behavioural elements have also pro-
duced encouraging results with abstinent cocaine users
[118]. For example, in two studies involving 90 severely
disadvantaged cocaine users (88 per cent of whom were
using crack cocaine), Kirby and colleagues investigated
the effect of adding voucher payments for cocaine-free
urine screens to a comprehensive treatment package
[119]. The treatment package was delivered over three
months and comprised 26 sessions of cognitive-behav-
ioural therapy and 10 one-hour sessions of inter-
personal problem-solving. In the first study, voucher
delivery was on a weekly basis with initial values low,
increasing with production of consecutive negative
results, and reset to zero on production of positive
screens. In that study the use of vouchers was found to
have no effect. The second study involved 23 subjects.
Half the group received vouchers on a weekly basis,
while the other half received vouchers immediately on
producing the cocaine-free urine. There were significant
improvements on measures of abstinence for immediate
compared with weekly voucher delivery. About half the
participants on immediate voucher delivery completed
treatment and showed continuous abstinence at one
month following treatment, whereas none of the partic-
ipants on weekly voucher delivery achieved one month
of continuous abstinence. Another study examined the
effects of adding brief coping skills training or a control
“attention placebo” condition to a comprehensive treat-
ment package incorporating both 12-step and social
learning principles [120]. Both approaches were admin-
istered on an individual basis in eight one-hour sessions
with three to five sessions per week based on length of
stay. One hundred and eight subjects from an original
sample of 128 were considered to have received at least
50 per cent treatment exposure and 73 per cent of these
were approached for follow-up. There were no differen-
tial effects of the two additional interventions in terms
of total abstinence during the three-month follow-up
period. However, there were significant reductions in
days of use as well as length of bingeing for participants
in the coping skills treatment group compared with
those receiving a placebo. Overall, the authors conclud-
ed that the brief skills intervention led to shorter and
less severe relapses.
Trial evaluations have also provided good evidence for
the effectiveness of structured cognitive-behavioural
therapy with cocaine users compared with no-treatment
controls [121].However, a more useful test of cognitive-
behavioural therapy involves contrasts with existing
treatments. Here the evidence is somewhat mixed. In
one study, 42 dependent cocaine users were assigned at
random to receive a 12-week programme of individual
cognitive-behavioural therapy or interpersonal psycho-
therapy [18]. Results showed that the cognitive-behav-
ioural therapy patients were more likely to complete
treatment (67 per cent versus 38 per cent), achieve three
or more continuous weeks of abstinence (57 per cent
versus 33 per cent) and be continuously abstinent for
four or more weeks after they left treatment (43 per cent
versus 19 per cent). Treatment gains were most evident
in a group of severe cocaine users, who were more likely
to achieve abstinence if assigned to receive cognitive-
behavioural therapy. Maude-Griffin and colleagues
assigned crack cocaine smokers at random to either cog-
nitive-behavioural therapy or 12-step counselling and
Cocaine Anonymous participation [122]. Participants
attended three group and one individual therapy session
per week over 12 weeks. Attendance at treatment groups
was low, with just 17 participants (13 per cent) attend-
ing at least 75 per cent of both group and individual ses-
sions. Overall 44 per cent of the cognitive-behavioural
group and 32 per cent of the 12-step facilitated group
achieved four consecutive weeks of abstinence from
cocaine. In another study, cocaine-dependent patients
who continued to use cocaine during a four-week inten-
sive outpatient treatment programme had much better
cocaine use outcomes if they subsequently received
aftercare that included a combination of group therapy
and a structured relapse prevention protocol delivered
through individual sessions rather than aftercare that
consisted of group therapy alone [123].
Community reinforcement and contingency 
contracting
In the late 1970s Azrin and colleagues developed the
community reinforcement approach as a treatment for
alcohol dependence with favourable results [124].
Using that model, Higgins and colleagues examined
multiple variations on the community reinforcement
approach with cocaine-dependent patients [118, 125,
126]. In their studies cocaine-dependent patients seek-
ing outpatient treatment were randomly assigned to
receive either standard drug counselling and referral to
Alcoholics Anonymous or a multi-component behav-
ioural treatment integrating contingency-managed
counselling, community-based incentives and family
therapy comparable to the community reinforcement
12
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approach model. The latter retained more patients in
treatment, produced more abstinent patients and
longer periods of abstinence and produced greater
improvements in personal function than the standard
counselling approach. Following the overall findings,
this group of investigators systematically “disassem-
bled” the community reinforcement approach model.
They examined the individual “ingredients” of family
therapy (incentives and contingency-based coun-
selling) by comparing outcomes for groups who
received comparable amounts of all components except
the target ingredient [118, 125, 127]. In each case,
their systematic and controlled examinations indicated
that the targeted individual component made a signif-
icant contribution to the outcomes observed, thus
proving their added value in the rehabilitation effort. 
Counsellor and therapist effects
Several studies have looked at the acquisition and influ-
ence of positive therapeutic working relationships
between the treatment therapist or counsellor and the
patient [29, 128, 129]. Therapeutic involvement (meas-
ured by rapport between counsellor and patient and the
patient's ratings of their commitment to treatment and
its perceived effectiveness) together with counselling ses-
sion attributes (the number of sessions attended and the
number of health and other topics discussed) have a
direct positive effect on retention [29]. These findings
are supported by several other valuable studies that sug-
gest that programme counsellors who possess strong
interpersonal skills, are organized in their work, see their
clients more frequently, refer clients to ancillary services
as needed and generally establish a practical and “thera-
peutic alliance” with the patient achieve better out-
comes [99, 130]. It is important to stress that not all
counsellors are equally effective with their patients
[131]. Differences in outcome are found between pro-
fessional psychotherapists with doctoral-level training
and among paraprofessional counsellors. For example,
Luborsky and colleagues found outcome differences in a
variety of areas among nine professional therapists pro-
viding ancillary psychotherapy to methadone mainte-
nance patients [132]. McLellan and the same group
found that assignment to one of five methadone main-
tenance counsellors resulted in significant differences in
treatment progress over the following six months [133].
Specifically, patients transferred to one counsellor
achieved significant reductions in illicit drug use, unem-
ployment and arrests, while concurrently reducing their
average methadone dose. In contrast, patients trans-
ferred to another counsellor showed increased unem-
ployment and illicit drug abuse as well as needing 
higher doses of methadone.
Participation in self-help groups
Narcotics Anonymous (and Cocaine Anonymous) are
peer-support networks of individuals who meet for the
purpose of supporting each other's efforts to maintain
sobriety and to lead productive, fulfilling lives. While
there has always been consensual agreement that peer-
support forms of treatment are valuable, evaluations of
the impact of meeting attendance has not been wide-
spread. McKay and colleagues found that participation in
post-treatment self-help groups predicted better outcome
among a group of cocaine- or alcohol-dependent veterans
in a day hospital rehabilitation programme [123].
“Matching” patients and treatments
There have been a substantial number of research stud-
ies that have attempted to “match” particular “kinds” of
patient with specific types, modalities or settings of
treatment. The approach to patient-treatment “match-
ing” that has received the greatest attention from sub-
stance abuse treatment researchers involves attempting
to identify the characteristics of individual patients that
predict the best response to different forms of addiction
treatments, such as cognitive-behavioural therapy versus
12-step, or inpatient versus outpatient [115]. In gene-
ral, the majority of these “patient-to-treatment” match-
ing studies have not shown robust or generalizable find-
ings [134]. Another approach to matching has been to
assess the nature and severity of patients' problems at
intake and then to “match” the specific and necessary
services to the particular problems presented at the
assessment. This has been called “problem-to-service”
matching [135]. This approach may have more practical
application as it is consonant with the “individually tai-
lored treatment” philosophy that has been espoused by
most practitioners. In this regard, McLellan and col-
leagues attempted to match problems to services in two
inpatient and two outpatient private treatment pro-
grammes [135]. Patients in the study were assessed at
intake and placed in a programme that was acceptable
to both the referrer and the patient. At intake, patients
were also assigned randomly to either the standard or
“matched” services conditions. In the standard condi-
tion, the treatment programme received assessment
information and personnel were instructed to treat the
patient in the “standard manner, as though there were
no evaluation study ongoing”. The programme staff was
instructed not to withhold any services from patients in
the standard condition. Patients who were randomly
assigned to the matched services condition were also
placed in one of the four treatment programmes and
assessment information was forwarded to that pro-
gramme. The programmes agreed to provide at least
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three individual sessions in the areas of employment,
family/social relations or psychiatric health delivered by
a professionally trained staff person to improve func-
tioning in those areas when a patient showed a signifi-
cant degree of impairment in one or more of the areas at
intake. In fact, matched patients received significantly
more psychiatric and employment services than stan-
dard patients, but similar family/social services or alco-
hol and drug services. Matched patients were also more
likely to complete treatment (93 per cent versus 81 per
cent), and showed more improvement in the areas of
employment and psychiatric functioning than the stan-
dard patients. Furthermore, they were also less likely to
be retreated for substance abuse problems after dis-
charge during the six-month follow-up. These findings
suggest that matching treatment services to adjunctive
problems can improve outcomes in key areas and may
also be cost-effective as they reduce the need for subse-
quent treatment due to relapse. 
Substance abusers with co-morbid psychiatric problems
may be particularly good candidates for the “problem-
to-service” matching approach, especially the addition
of specialized psychiatric services for those most severely
affected by psychiatric problems. As compared with less
structured interventions, highly structured relapse
revention interventions may also be more effective in
decreasing cocaine use in cocaine abusers with co-
morbid depression [136]. Woody and colleagues evalu-
ated the value of individual psychotherapy when added
to paraprofessional counselling services in the course of
methadone maintenance treatment [104]. Patients were
randomly assigned to receive standard drug counselling
alone or drug counselling plus one of two forms of pro-
fessional therapy (supportive-expressive psychotherapy
and cognitive-behavioural therapy) over a six-month
period. Results showed that patients receiving psy-
chotherapy showed greater reductions in drug use, more
improvements in health and personal function and
greater reductions in crime than those receiving coun-
selling alone. Stratification of patients according to their
levels of psychiatric symptoms at intake showed that the
main psychotherapy effect was seen in those with greater
than average levels of psychiatric symptoms. Specifically,
patients with low symptom levels made considerable
gains with counselling alone and there were no differ-
ences between types of treatment. However, patients
with more severe psychiatric problems showed few gains
with counselling alone but substantial improvements
with the addition of the professional psychotherapy. 
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In this review, we have briefly discussed the substance
abuse treatment research literature and identified
patient and treatment-related variables associated with
outcome. There is an established evidence base for the
effectiveness of both the detoxification-stabilization
phase and rehabilitation-relapse prevention phase.
There is no simplistic summary that can be given for
this body of work. However, there is strong evidence to
show that treatment programmes are able to meet their
goals and objectives and confer important benefits on
patients, their families and the wider community and
society. There are differences in outcome associated with
different types of treatment approach, setting, medica-
tion and patient group.
4. Conclusion
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